Semnur Pharmaceuticals, Inc.
SMNRW- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001913577
No open-market purchases or sales by Semnur Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesSMNR
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SMNRW, Q2 2026
No superinvestor reported holding SMNRW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Semnur Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2025 (view filing)7:49 PM ET | Sep 23 | 2 days | Scilex Holding Co and 1 other10% Owner | SSale | −11.9M | $16.00 | −$191.1M | −6.2%181.8M after | |
| Sep 25, 2025 (view filing)7:49 PM ET | Sep 23 | 2 days | Scilex Holding Co and 1 other10% Owner | SSale | −554.8K | $16.00 | −$8.88M | −52.6%500.0K after | |
| Sep 16, 2024 (view filing) | Aug 30 | 17 daysLate | Denali Capital Global Investments LLC10% Owner | SSaleClass B Ordinary Shares | −500.0K | – | – | –1.43M after | DerivativeDuplicate filing |
| Sep 16, 2024 (view filing) | Aug 30 | 17 daysLate | Xu Jiandong10% Owner | SSaleClass B Ordinary Shares | −500.0K | – | – | –1.43M after | Derivative |
| Apr 13, 2022 (view filing) | Apr 11 | 2 days | Denali Capital Global Investments LLC10% Owner | PPurchaseClass A Ordinary Shares | +510.0K | $10.00 | +$5.10M | New position510.0K after | Duplicate filing |
| Apr 13, 2022 (view filing) | Apr 11 | 2 days | Xu Jiandong10% Owner | PPurchaseClass A Ordinary Shares | +510.0K | $10.00 | +$5.10M | New position510.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Semnur Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding SMNRW in 13F filings for Q2 2026.